Change in matrix metalloproteinase 2, 3, and 9 levels at the time of and after acute atherothrombotic myocardial infarction

Owolabi, Ugochukwu; Amraotkar, Alok R.; Coulter, Amanda R.; Singam, Narayana Sarma V.; AlAdili, Bahjat; Singh, Ayesha; Trainor, Patrick J.; Mitra, Riten; DeFilippis, Andrew P.

doi:10.1007/s11239-019-02004-7

Cited by 23 publications

(23 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The increased circulating levels of MMP 2, 3, 9 and 28 in AMI do not distinguish between atherothrombotic and non-atherothrombotic events. [ 70 , 73 ].…”

Section: Newer Biomarkers For Laboratory Diagnosis Of Acute Myocardial Infarctionmentioning

confidence: 99%

Past, Present, and Future of Blood Biomarkers for the Diagnosis of Acute Myocardial Infarction—Promises and Challenges

Ţilea

Varga

Șerban³

2021

Diagnostics

View full text Add to dashboard Cite

Despite important advancements in acute myocardial infarction (AMI) management, it continues to represent a leading cause of mortality worldwide. Fast and reliable AMI diagnosis can significantly reduce mortality in this high-risk population. Diagnosis of AMI has relied on biomarker evaluation for more than 50 years. The upturn of high-sensitivity cardiac troponin testing provided extremely sensitive means to detect cardiac myocyte necrosis, but this increased sensitivity came at the cost of a decrease in diagnostic specificity. In addition, although cardiac troponins increase relatively early after the onset of AMI, they still leave a time gap between the onset of myocardial ischemia and our ability to detect it, thus precluding very early management of AMI. Newer biomarkers detected in processes such as inflammation, neurohormonal activation, or myocardial stress occur much earlier than myocyte necrosis and the diagnostic rise of cardiac troponins, allowing us to expand biomarker research in these areas. Increased understanding of the complex AMI pathophysiology has spurred the search of new biomarkers that could overcome these shortcomings, whereas multi-omic and multi-biomarker approaches promise to be game changers in AMI biomarker assessment. In this review, we discuss the evolution, current application, and emerging blood biomarkers for the diagnosis of AMI; we address their advantages and promises to improve patient care, as well as their challenges, limitations, and technical and diagnostic pitfalls. Questions that remain to be answered and hotspots for future research are also emphasized.

show abstract

“…The increased circulating levels of MMP 2, 3, 9 and 28 in AMI do not distinguish between atherothrombotic and non-atherothrombotic events. [ 70 , 73 ].…”

Section: Newer Biomarkers For Laboratory Diagnosis Of Acute Myocardial Infarctionmentioning

confidence: 99%

Past, Present, and Future of Blood Biomarkers for the Diagnosis of Acute Myocardial Infarction—Promises and Challenges

Ţilea

Varga

Șerban³

2021

Diagnostics

View full text Add to dashboard Cite

show abstract

“…The patients with the following characteristics and clinical presentations were included in the study: (1) all the subjects met the latest diagnostic criteria for AMI [8,9]. (2) The patient received emergency coronary intervention for the first time. All patients with AMI were treated with standard percutaneous coronary intervention, and coronary angiography was performed through the radial artery or the femoral artery.…”

Section: Patient Selectionmentioning

confidence: 99%

“…Acute myocardial infarction (AMI) is a common cardiovascular disease [1]. Extracellular matrix is considered a dynamic constantly remodeling structure that plays a pivotal role in myocardial repair [2]. Matrix metalloproteinases (MMPs) play a pivotal role in postmyocardial infarction cardiac remodeling as well as in the development of adverse outcomes [3].…”

Section: Introductionmentioning

confidence: 99%

Circulating Matrix Metalloproteinase-28 Levels Are Related to GRACE Scores and Short-Term Outcomes in Patients with Acute Myocardial Infarction

Zhou

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Objective. To investigate the relationship between the level of matrix metalloproteinase-28 (MMP-28) in patients with acute myocardial infarction (AMI) and the global registry of acute coronary events (GRACE) scores as well as their short-term prognosis. Methods. Two hundred eleven patients with AMI were enrolled, and their basic clinical characteristics were collected for determining the GRACE score. We measured the plasma levels of MMP-28 and other biomarkers in the study population. The association of MMP-28 levels with cardiac events and cardiac deaths occurring within 30 days of discharge was evaluated with multivariable Cox proportional hazard models. Results. The MMP-28 levels were significantly higher in patients with acute ST-elevation myocardial infarction (STEMI) than in patients with non-ST-elevation myocardial infarction (NSTEMI) (P<0.01). Correlation analysis showed that the level of MMP-28 was positively correlated with the GRACE score in patients with AMI (R2=0.366, P<0.05). Cox multivariate regression results showed that MMP-28 was associated with cardiovascular events during the hospitalization and 30 days after discharge (P<0.01). In addition, Kaplan–Meier analysis showed that cardiac events and deaths were significantly higher in patients with MMP-28≥1.21 ng/mL (all P<0.01). Conclusion. There is a correlation between the plasma MMP-28 level and GRACE score in patients with AMI. MMP-28 is also associated with cardiovascular events and cardiovascular deaths during the hospitalization of patients and within 30 days of discharge.

show abstract

“…The findings suggested the role of gene-based cell proliferation in ISRs, hinting at the role of ECM interaction with the stents in cardiac tissue repair. Similarly, MMP-2 and -9 also play an important role in acute MI and cardiac tissue repair [53] . Hence, addition/delivery of these proteins may play a pivotal role in designing PCI with effective cardiac tissue repair.…”

Section: Ecm Hydrogels In Cardiac Tissue Repairmentioning

confidence: 99%

Nanomaterial-based hydrogels for coronary interventions: a mini review

Saxena¹,

Pandey²

2020

Mini-invasive Surg

View full text Add to dashboard Cite

Myocardial infarction (MI) has become a major health concern these days. Elevated levels of cholesterol due to improper diet cause severe damage to human health, resulting in the narrowing of blood vessels leading to MI. Different approaches have been used based on surgical and non-surgical treatments for these blockages to cure MI. In this regard, injectable and non-injectable hydrogel-based percutaneous coronary intervention has shown promising applicability for the treatment of cardiac damage and its repair. In this report, we summarize a few hydrogels based on natural polymers such as chitosan, alginate, polyethylene glycol and extracellular matrices to be used for percutaneous coronary intervention in the treatment of MI. Their structure, biological properties and biocompatibilities are discussed, and their existing challenges are also detailed. In addition, the probable solutions to overcome certain set backs are also highlighted.

show abstract

Change in matrix metalloproteinase 2, 3, and 9 levels at the time of and after acute atherothrombotic myocardial infarction

Cited by 23 publications

References 50 publications

Past, Present, and Future of Blood Biomarkers for the Diagnosis of Acute Myocardial Infarction—Promises and Challenges

Past, Present, and Future of Blood Biomarkers for the Diagnosis of Acute Myocardial Infarction—Promises and Challenges

Circulating Matrix Metalloproteinase-28 Levels Are Related to GRACE Scores and Short-Term Outcomes in Patients with Acute Myocardial Infarction

Nanomaterial-based hydrogels for coronary interventions: a mini review

Contact Info

Product

Resources

About